Agent could guide more precise removal of brain tumors | SPECT/CT imaging useful for guiding back pain treatment, study finds | Compound targets enzyme in brain cancer
Web Version
 
August 26, 2014
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals
SIGN UP|FORWARD|ARCHIVE|ADVERTISE

Top Story
Agent could guide more precise removal of brain tumors
Scientists have created a nanoparticle contrast agent, consisting of a dye-coated gold core with a crust of silica, that highlights tumor margins during brain surgery. Researchers tested the agent in mice with glioblastoma tumors. Using a handheld Raman scanner, they found clusters of cancer that were not detectable with normal light or a Raman microscope. Details of the study appear in the journal ACS Nano. Chemical & Engineering News (8/25)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical News & Research
SPECT/CT imaging useful for guiding back pain treatment, study finds
A study that reviewed data from 29 patients with low back pain revealed that SPECT/CT data changed management in 76% of patients and could rule out the possibility of infection and distinguish joint and discogenic pain. Details of the study will be discussed at the Royal College of Radiologists Annual Scientific Meeting in London. Diagnostic Imaging (8/25)
Share: LinkedInTwitterFacebookGoogle+Email
Compound targets enzyme in brain cancer
Scientists have developed a neuraminidase inhibitor, targeting an enzyme that is highly expressed in some types of cancer. Researchers found the compound halted growth and appeared to convert glioblastoma cancer stem cells into healthy cells, suggesting the compound has properties that may be used to develop treatments to fight the disease. The study appeared in the journal Cell Death & Disease. Counsel & Heal (8/23)
Share: LinkedInTwitterFacebookGoogle+Email
Industry Report
$1.5M contract awarded to advance Telik's pancreatic cancer tracer
Telik has received a $1.5 million contract supported by the National Cancer Institute for the development of a pancreatic cancer PET imaging agent. The company's radiolabeled 5B1 antibody targets a carbohydrate antigen that is heavily expressed in gastric and pancreatic cancer cells. The project involves MabVax Therapeutics, recently merged with Telik, and Memorial Sloan Kettering Cancer Center. MolecularImaging.net (8/25)
Share: LinkedInTwitterFacebookGoogle+Email
News from the Field
ABIM weighs issues with MOC grandfathering
The American Board of Internal Medicine says it is looking at problems with its Maintenance of Certification language and reporting with respect to grandfathered physicians who can opt out of MOC requirements. The American Board of Medical Specialties website does not list grandfathered doctors as meeting MOC requirements, something Dr. Mack Harrell, president of the American Association of Clinical Endocrinologists, calls "a scarlet letter." Clinical Endocrinology News (8/22)
Share: LinkedInTwitterFacebookGoogle+Email
Medtech sector struggling to adopt digital technology, report finds
The medical device industry appears to be lagging behind other sectors in terms of digital technology adoption, according to a PricewaterhouseCoopers report. Industry leaders see the value in digital technology, the report found, but 75% of medtech executives said their firms were having difficulty adopting tools such as social media, data mining and mobile applications. MassDevice.com (Boston) (8/25)
Share: LinkedInTwitterFacebookGoogle+Email
Advancing Health Care
Study: Telemedicine shows promise in boosting access to stroke care
A study in the journal Stroke found that telemedicine can boost access to stroke care for patients in rural communities. Researchers found a correlation between the implementation of a telemedicine network and a significant increase in the proportion of people treated for transient ischemic attack and stroke at facilities with telestroke units. The study examined data from February 2003 to December 2012. PhysiciansBriefing.com/HealthDay News (8/22)
Share: LinkedInTwitterFacebookGoogle+Email
From SNMMI
SNMMI 2014 Patient Hill Day -- Sept. 29-30 in Washington, D.C.
SNMMI will once again be holding a patient-focused Hill Day to bring patient advocates to talk to their Senate and House representatives about how imaging made a difference in their lives. Learn more about the key issues to be covered and how you can get involved.
Share: LinkedInTwitterFacebookGoogle+Email
Earn AMA PRA Category 1 Creditâ„¢, ACPE or VOICE credit
Earn CE credit with SNMMI's comprehensive online lectures. Popular lectures include Basic Science -- Basic Atomic and Nuclear Physics, Brain Amyloid Imaging, FDA Audits and Inspections: A Manufacturer's Perspective, Computers in Nuclear Medicine (CA Scope: NI) and Molecular Imaging & Prostate Cancer. Select your credit type and get started today. AMA PRA Category 1 Credit™, ACPE or VOICE.
Share: LinkedInTwitterFacebookGoogle+Email
SmartQuote
The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails."
-- William Arthur Ward,
American writer
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about SNMMI ->SNMMI | News | Meetings | Education | Publications | Membership
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Melissa Turner
Advertising:  Meryl Harold
  P: 202.407.7828
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information